Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/50678
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHuynh, H.en
dc.contributor.authorCampbell, M.en
dc.contributor.authorCouper, R.en
dc.contributor.authorTran, C.en
dc.contributor.authorLawrence, A.en
dc.contributor.authorButler, R.en
dc.date.issued2009en
dc.identifier.citationLetters in Applied Microbiology, 2009; 48(5):517-522en
dc.identifier.issn0266-8254en
dc.identifier.issn1472-765Xen
dc.identifier.urihttp://hdl.handle.net/2440/50678-
dc.descriptionJournal compilation © 2009 The Society for Applied Microbiologyen
dc.description.abstractAims: To evaluate the efficacy of bovine lactoferrin (BLf), recombinant human lactoferrin (rHLf) and desferrioxamine against Helicobacter pylori in vitro and in mice and also to determine whether BLf or rHLf alter gastric inflammation. Methods and Results: In vitro: Broth dilution susceptibility tests were performed using different concentrations of desferrioxamine, BLf and rHLf. Murine trials: In the prevention trial, C57BL/6 female mice were treated with BLf or rHLF, and then infected with the SS1 strain of H. pylori. In the treatment trial, mice were gavaged with either BLf, rHLf or desferrioxamine. In addition, gastric myeloperoxidase activity (MPO) was measured to assess gastric inflammation. Desferoxamine was found to have a direct bactericidal effect, while BLf and rHLf only partially suppressed H. pylori growth in vitro. However, in both prevention and treatment trials all three forms of treatment failed to reduce H. pylori load in mice. Gastric MPO activity and H. pylori load were noted to be higher with lactoferrin treatments. Conclusions: Our study does not support the use of BLf or rHLF in the treatment of human H. pylori infection. Interestingly, H. pylori growth and gastric inflammation appear to be enhanced by lactoferrin treatment.en
dc.description.statementofresponsibilityH.Q. Huynh, M.A.F. Campbell, R.T.L. Couper, C.D. Tran, A. Lawrence and R.N. Butleren
dc.language.isoenen
dc.publisherBlackwell Science Ltden
dc.subjectdesferrioxamine; Helicobacter pylori infection; iron chelating agent; lactoferrin; mice; MPOen
dc.titleLactoferrin and desferrioxamine are ineffective in the treatment of Helicobacter pylori infection and may enhance H-pylori growth and gastric inflammation in miceen
dc.typeJournal articleen
dc.identifier.rmid0020090491en
dc.identifier.doi10.1111/j.1472-765X.2009.02557.xen
dc.identifier.pubid39044-
pubs.library.collectionPaediatrics publicationsen
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidTran, C. [0000-0001-9220-2715]en
Appears in Collections:Paediatrics publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.